Skip to main content
impaact logo Return to homepage
  • Contact
    • Directory
  • About
    • Mission
    • Network Structure
      • Leadership
    • Areas of Research
      • HIV Complications and Co-Morbidities
      • HIV Cure
      • HIV Treatment
      • Tuberculosis
    • Funding Acknowledgements
    • Network Sites
    • Staff Spotlight
  • Studies
    • Research and Study Opportunities
    • Submit a Research Proposal
    • IMPAACT Study Snapshots
  • Community Engagement
    • ICAB Leadership Group
    • IMPAACT Community Advisory Board (ICAB)
    • Operations Center Staff
    • Resources
      • Acronyms
    • Site Community Advisory Boards
  • News & Events
    • Conferences & Other Meetings
    • IMPAACT Annual Meeting
    • Newsletters
    • Past Conference Presentations
  • Resources
    • COVID-19 Resources
    • HIV/AIDS Network Coordination (HANC)
    • Lab Center
      • Laboratory Committees
      • Laboratory Guidance Documents
      • Laboratory Resources for Quality Management
      • Specimen Repository
    • Manual of Procedures
    • Network Logos & Templates
    • Regulatory Resources
    • Training Opportunities
  • Publications
    • Abstracts
    • Manuscripts
  • Enter a search term.
Back to Directory

Elizabeth (Betsy) McFarland

Email

Phone

Institution

Children’s Hospital Colorado

Role

MD Principal Investigator

Address

Univeristy of Colorado Denver
Department of Pediatrics
13123 E. 16th Ave. B055
Aurora, CO 80045
United States
Request an Update

Affiliated Studies

P1015: Cycling HAART in Pediatric/Adolescent Patients with < 50 HIV RNA copies/mL.

DAIDS Number

10267

Research Area

Other

Study Status

Concluded

Locality

Not Applicable

IMPAACT 2008: Phase I/II Multisite, Randomized, Controlled Study of Monoclonal Antibody VRC01 with Combination Antiretroviral Therapy to Promote Clearance of HIV-1-Infected Cells in Infants

DAIDS Number

20735

Research Area

Cure

Study Status

Closed to Follow Up

Locality

US & Non-US

P1053: Evaluation PI-Containing vs. Non-PI-Containing Salvage Regimens.

DAIDS Number

10131

Research Area

Other

Study Status

Concluded

Locality

United States

IMPAACT 2011: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID delta M2-2 1030s, Lot RSV#010A, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age

DAIDS Number

30072

Research Area

Complications & Comorbidities

Study Status

Concluded

Locality

United States

P1094: Evaluation of the use 3TC

DAIDS Number

11769

Research Area

Other

Study Status

Concluded

Locality

US & Non-US
Show All
IMPAACT logo Return to homepage

Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.

Stay connected with the IMPAACT Network

Follow IMPAACT

Sign up for our newsletter

Sitemap

© 2020 IMPAACT Network